- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00916383
Study in Elderly Alzheimer's Patients to Assess Skin Tolerability, Irritation With 3, 7-Day Applications of DTP-System (DTP-System)
Randomized, Placebo-Controlled Study in Elderly Alzheimer's Patients on Established/Well Tolerated Dose of Aricept to Assess Skin Tolerability, Irritation, Adhesion With 3 Consecutive 7-Day Applications of 350 mg Donepezil Transdermal Patch
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, placebo-controlled study designed to evaluate skin irritation, skin tolerability, and adhesion of the 350 mg DTP-system following 3 consecutive 7-day applications to 3 specific areas of the body (upper back, upper arm, side of torso) of elderly Alzheimer's patients. The total exposure time for the DTP-system is 21 days.
All patients receive 1 Donepezil Transdermal Patch (DTP-system) and 1 placebo patch, each applied to opposite sides of the body (e.g., placebo patch to the left side of the upper back, and DTP-system to the right side of the upper back). Patients are randomized to receive the active patch to either the left or the right side of the body according to 1 of 6 treatment sequences listed below. The treatment sequence is repeated for the opposite side of the body for a total of 12 treatment sequences (4 patients in each treatment sequence). The patches are applied to one of 3 body locations for 7 days, for a total exposure period of 21 days, according to one of the following sequences:
- Upper Back, Upper Arm, Side of Torso (Right)
- Upper Arm, Side of Torso, Upper Back (Right)
- Side of Torso, Upper Back, Upper Arm (Right)
- Upper Back, Side of Torso, Upper Arm (Right)
- Upper Arm, Upper Back, Side of Torso (Right)
- Side of Torso, Upper Arm, Upper Back (Right)
- Upper Back, Upper Arm, Side of Torso (Left)
- Upper Arm, Side of Torso, Upper Back (Left)
- Side of Torso, Upper Back, Upper Arm (Left)
- Upper Back, Side of Torso, Upper Arm (Left)
- Upper Arm, Upper Back, Side of Torso (Left)
- Side of Torso, Upper Arm, Upper Back (Left)
Patches are applied on Days 1, 8, and 15 according to the randomization schedule. Oral Aricept is taken daily through Day -1, and is re-started on Day 22 or at the time of early termination if before Day 22. Patients are seen in the clinic at Screening and on Days 1, 8, 15, 22, and at the End of Study Visit; for all other daily visits, the patients may be seen either at the clinic or in their residence, provided the assessments are completed as described in the protocol. Skin irritation is assessed immediately upon patch removal and at 1, 24, and 48 hours after removal.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85004
- Xenoscience, Inc
-
-
California
-
Fresno, California, United States, 93720
- Margolin Brain Institute
-
Garden Grove, California, United States, 92845
- Collaborative Neuroscience Network, Inc
-
National City, California, United States, 91950
- Synergy Clinical Research Center
-
Santa Ana, California, United States, 92705
- Apex Research Institute
-
-
Florida
-
Brooksville, Florida, United States, 34613
- Meridien Research
-
Miami, Florida, United States, 33137
- Miami Jewish Home and Hospital for the Aged
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female at least 65 years of age.
- Established dose of Aricept 10 mg at least 2 months prior to enrollment.
- Established diagnosis of stable Alzheimer's disease treated with oral Aricept
- Must be willing to change from oral Aricept to DTP (and placebo patch).
- Body mass index of at least 18 and a minimum weight of at least 45 kg.
- Blood pressure (sitting) must be diastolic <95mmHg, and systolic <145, stable for at least 3 months. Patients with well-controlled hypertension (with medication) may enroll as long as 3-month stability criterion is met.
- Those with stable cardiac disease may be enrolled provided the patient has been on appropriate medication for 3 months prior to screening. Those with a pacemaker may be enrolled.
- Pulse rate between 45 - 100 bpm; respirations between 8 - 20 per minute.
- Those with thyroid disease may enroll if stable on treatment for at least 3 months prior to screening, and maintain the same dose of thyroid medication throughout the study.
- Must have a caregiver who is either living with the patient or is in daily contact with the patient, agrees to be present at all visits, provide information as required, and ensure compliance with the medication schedule.
- Free from any abnormality at Screening which may compromise the patient's ability to participate.
- Free of any dermatologic conditions, excessive hair or skin allergies and sensitivities.
- Male patients who have female partners of childbearing potential must use a condom.
- Must understand and provide written informed consent (or have a Legally Authorized Representative who is able), prior to the initiation of any protocol-specific procedures.
- Must be willing and able to abide by all study requirements and restrictions.
- Must be on stable medications for at least 30 days prior to enrollment into the study.
Exclusion Criteria:
- Use of systemic or topical antihistamines within 72 hours prior to enrollment, or systemic or topical corticosteroids within 3 weeks of study enrollment or foreseen use during the study.
- History of allergy to Donepezil hydrochloride or to piperidine derivatives, related drugs, or any of the drug excipients or other drug product components.
- Those with a recent (< 2 years) cancer (except for non-melanoma skin cancers, females with in-situ cancer of the cervix or males with localized prostate cancer requiring no treatment).
- Presence of history of a psychiatric disorder, or other seizure disorder deemed clinically significant.
- Those with a known plan for elective surgery during the study period.
- Those taking antidepressant medication.
- Abnormality (e.g., scar, tattoo) or unhealthy skin (e.g., burns, wounds) at the application site; or an existing chronic skin disease or history of skin disease at the application site(s) within the 30 days prior to enrollment.
- Treatment with any investigational drug within 30 days prior to enrollment in the study.
- Any condition which would make the patient or caregiver, in the opinion of the investigator or designee, not suitable for the study for any reason.
- Current or pending legal charges that may affect patient or caregiver compliance.
- Treatment with medications contraindicated for use with Aricept
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Upper Back
350 mg Donepezil Transdermal Patch (active) and placebo patch, each applied to opposite sides of the upper back.
|
Active and placebo patches will be applied to opposite sides for 7 days.
Active and placebo patches will be applied to opposite sides for 7 days.
|
Experimental: Upper Arm
350 mg Donepezil Transdermal Patch (active) and placebo patch, each applied to opposite arms.
|
Active and placebo patches will be applied to opposite sides for 7 days.
Active and placebo patches will be applied to opposite sides for 7 days.
|
Experimental: Side of Torso
350 mg Donepezil Transdermal Patch (active) and placebo patch, each applied to opposite sides of torso.
|
Active and placebo patches will be applied to opposite sides for 7 days.
Active and placebo patches will be applied to opposite sides for 7 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Skin Irritation (Erythema and Edema)
Time Frame: Immediately after patch removal
|
Erythema and edema were used to determine skin irritation using a modified Draize scale.
Score 0 = no erythema/edema; Score 1 = very slight erythema/edema; Score 2 = well-defined erythema/slight edema; Score 3 = moderate to severe erythema/edema; Score 4 = severe erythema/edema.
|
Immediately after patch removal
|
Skin Irritation (Erythema)
Time Frame: 1, 24, and 48 hours after patch removal (Days 8-10; Days 15-17; Days 22-24)
|
Erythema was used to determine skin irritation using a modified Draize scale.
Score 0 = no erythema; Score 1 = very slight erythema; Score 2 = well-defined erythema; Score 3 = moderate to severe erythema; Score 4 = severe erythema.
|
1, 24, and 48 hours after patch removal (Days 8-10; Days 15-17; Days 22-24)
|
Skin Irritation (Edema)
Time Frame: 1, 24, and 48 hours after patch removal (Days 8-10; Days 15-17; Days 22-24)
|
Edema was used to determine skin irritation using a modified Draize scale.
Score 0 = no edema; Score 1 = very slight edema; Score 2 = slight edema; Score 3 = moderate to severe edema; Score 4 = severe edema.
|
1, 24, and 48 hours after patch removal (Days 8-10; Days 15-17; Days 22-24)
|
Skin Irritation (Papules and Vesicles)
Time Frame: Immediately after patch removal
|
Papules and vesicles were assessed according to the following scoring criteria: Score 0 = no evidence of papules or vesicles; Score 1 = few papules or vesicles (< 10) observed on the skin site; Score 2 = more papules or vesicles (≥ 10) observed on < 50 % of skin site, diffuse or few clusters; Score 3 = many papules or vesicles observed on ≥ 50% of skin site, diffuse or few clusters; Score 4 = many papules or vesicles observed on > 50% of skin site, with multiple (> 3) clusters.
|
Immediately after patch removal
|
Skin Irritation (Papules and Vesicles)
Time Frame: 1, 24, and 48 hours after patch removal (Days 8-10; Days 15-17; Days 22-24)
|
Papules and vesicles were assessed according to the following scoring criteria: Score 0 = no evidence of papules or vesicles; Score 1 = few papules or vesicles (< 10) observed on the skin site; Score 2 = more papules or vesicles (≥ 10) observed on < 50 % of skin site, diffuse or few clusters; Score 3 = many papules or vesicles observed on ≥ 50% of skin site, diffuse or few clusters; Score 4 = many papules or vesicles observed on > 50% of skin site, with multiple (> 3) clusters.
|
1, 24, and 48 hours after patch removal (Days 8-10; Days 15-17; Days 22-24)
|
Skin Irritation (Other Skin Effects)
Time Frame: Immediately after patch removal
|
Other skin effects were assessed according to the following scoring criteria: Score 0 = no other effects observed; Score 1 = slight glazed appearance; Score 2 = marked glazing; Score 3 = glazing with peeling and cracking; Score 4 = glazing with fissures; Score 5 = film of dried serous exudate covering all or part of the patch site; Score 6 = small petechial erosions and/or scabs.
|
Immediately after patch removal
|
Skin Irritation (Other Skin Effects)
Time Frame: 1, 24, and 48 hours after patch removal (Days 8-10; Days 15-17; Days 22-24)
|
Other skin effects were assessed according to the following scoring criteria: Score 0 = no other effects observed; Score 1 = slight glazed appearance; Score 2 = marked glazing; Score 3 = glazing with peeling and cracking; Score 4 = glazing with fissures; Score 5 = film of dried serous exudate covering all or part of the patch site; Score 6 = small petechial erosions and/or scabs.
|
1, 24, and 48 hours after patch removal (Days 8-10; Days 15-17; Days 22-24)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety, Tolerability, and Adhesion
Time Frame: Safety was assessed throughout the study. Adhesion was assessed daily and immediately prior to patch removal on Days 8, 15, and 22.
|
See Adverse Event section for Safety assessment.
Adhesion was assessed according to the following scoring criteria: Score 0 = approximately > 90% adhered (essentially no lift off the skin); Score 1 = approximately 75% to < 90% adhered (some edges only lifting off the skin); Score 2 = approximately 50% to < 75% adhered (less than half of the system lifting off the skin); Score of 3 = approximately < 50% adhered but not detached (more than half of the system lifting off the skin without falling off); Score of 4 = Patch-system detached (patch /overlay completely off the skin).
|
Safety was assessed throughout the study. Adhesion was assessed daily and immediately prior to patch removal on Days 8, 15, and 22.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TPU-TAD-US02-0810
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Irritation/Irritant
-
Pulmatrix Inc.Completed
-
Amazentis SAPrinceton Research CorporationCompletedIrritation/Irritant | SensitisationUnited Kingdom
-
Next Science TMTKL Research, Inc.CompletedHealthy | Irritation/Irritant | Reactions Adverse
-
University of Split, School of MedicineRecruitingIrritation/Irritant | Antiseptic | ICD - Irritant Contact DermatitisCroatia
-
Galderma R&DCompleted
-
University Hospitals Cleveland Medical CenterNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaboratorsCompleted
-
Ventrus Biosciences, IncUnknownSkin IrritationUnited States
-
Galderma R&DCompletedSkin IrritationUnited States
-
LEO PharmaCompleted
-
Oxford Pharmascience LtdCompletedNSAID Related Gastric IrritationUnited Kingdom
Clinical Trials on 350 mg Donepezil Transdermal Patch
-
UCB BIOSCIENCES GmbHCompleted
-
Bausch Health Americas, Inc.Completed
-
Mundipharma Pte Ltd.Mundipharma Korea Ltd; Mundipharma (Hong Kong) Ltd; Mundipharma Distribution...CompletedOsteoarthritis | Rheumatoid Arthritis | Lower Back Pain | Joint Pain | Muscle PainHong Kong, Korea, Republic of, Philippines
-
University of Illinois at ChicagoRecruitingSuicidal IdeationUnited States
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)CompletedSuicidal IdeationUnited States
-
Agile TherapeuticsCompleted
-
National Institute on Drug Abuse (NIDA)CompletedSchizophrenia | Tobacco Use Disorder | Schizophrenia and Disorders With Psychotic FeaturesUnited States
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Vibe G Frøkjær, MD, PhDHvidovre University Hospital; Herlev HospitalRecruiting
-
University of Maryland, BaltimoreFood and Drug Administration (FDA)Completed